|
|
|
|
| LEADER |
01000caa a22002652 4500 |
| 001 |
NLM040405346 |
| 003 |
DE-627 |
| 005 |
20250127052809.0 |
| 007 |
tu |
| 008 |
231221s1985 xx ||||| 00| ||eng c |
| 028 |
5 |
2 |
|a pubmed25n0135.xml
|
| 035 |
|
|
|a (DE-627)NLM040405346
|
| 035 |
|
|
|a (NLM)4059288
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Belli, L
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Treatment of superficial candidiasis with bifonazole 1% gel
|
| 264 |
|
1 |
|c 1985
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ohne Hilfsmittel zu benutzen
|b n
|2 rdamedia
|
| 338 |
|
|
|a Band
|b nc
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 18.12.1985
|
| 500 |
|
|
|a Date Revised 23.11.2016
|
| 500 |
|
|
|a published: Print
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a Sixty-one patients with superficial candidiasis, confirmed on entry by clinical examination and mycological culture, were treated with a single daily application of a 1% bifonazole gel over a period of 4 weeks. Patients were seen every week during treatment and then followed-up for 2 weeks. An overall assessment of response to treatment, based on the clinical and mycological culture findings at the 14-day follow-up visit, showed that the results were very good in 49 and moderate in 9 patients, with only 3 patients being considered as failing to respond. Local tolerance was very good, but burning was reported by 1 patient, burning and itching by 1, and ardor and irritation by one. All these side-effects occurred at the start of treatment and they subsided without interruption of bifonazole treatment
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
7 |
|a Antifungal Agents
|2 NLM
|
| 650 |
|
7 |
|a Gels
|2 NLM
|
| 650 |
|
7 |
|a Imidazoles
|2 NLM
|
| 650 |
|
7 |
|a bifonazole
|2 NLM
|
| 650 |
|
7 |
|a QYJ305Z91O
|2 NLM
|
| 700 |
1 |
|
|a Galimberti, R
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Negroni, R
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Rohwedder, R W
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Castro, J M
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Pharmatherapeutica
|d 1985
|g 4(1985), 2 vom: 15., Seite 102-5
|w (DE-627)NLM023961570
|x 0308-051X
|7 nnns
|
| 773 |
1 |
8 |
|g volume:4
|g year:1985
|g number:2
|g day:15
|g pages:102-5
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_11
|
| 912 |
|
|
|a GBV_ILN_22
|
| 912 |
|
|
|a GBV_ILN_24
|
| 912 |
|
|
|a GBV_ILN_31
|
| 912 |
|
|
|a GBV_ILN_39
|
| 912 |
|
|
|a GBV_ILN_40
|
| 912 |
|
|
|a GBV_ILN_72
|
| 912 |
|
|
|a GBV_ILN_120
|
| 912 |
|
|
|a GBV_ILN_121
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 4
|j 1985
|e 2
|b 15
|h 102-5
|